Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (2025)

AMARIN CORPORATION PLC

Add to a list

To use this feature you must be a member

Log inSign up

Equities

AMRN

US0231112063

Market Closed - Nasdaq

Other stock markets

04:00:00 2024-05-17 pm EDT
5-day change 1st Jan Change
0.87 USD -4.65% Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (2) +2.05% 0.00%
May. 13 European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
May. 10 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
Days Hours Minutes Seconds -40% on all our subscriptions* Last Hours! Take advantage of the offer * See conditions on site

Financials (USD)

Sales 2024 * 202M Sales 2025 * 215M Capitalization 357M
Net income 2024 * -70M Net income 2025 * -64M EV / Sales 2024 * 1.55x
Net cash position 2024 * 43.92M Net cash position 2025 * 159M EV / Sales 2025 * 0.93x
P/E ratio 2024 *

-4.93x

P/E ratio 2025 *

-5.23x

Employees -
Yield 2024 *

-

Yield 2025 *

-

Free-Float 90.48%

More Fundamentals * Assessed data

Latest news about Amarin Corporation plc

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
Transcript : Amarin Corporation plc, Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q1 Revenue $56.5M MT
Amarin Corporation plc announces an Equity Buyback for $50 million worth of its shares. CI
Amarin Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Amarin Corporation plc authorizes a Buyback Plan. CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT

More news

Latest transcript on Amarin Corporation plc

Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (4)

Amarin Corporation plc, Q1 2024 Earnings Call, May 01, 2024

More transcripts

Analyst Recommendations on Amarin Corporation plc

Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3 MT
Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating MT
Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30 MT
European Equities Follow US Markets Lower on Interest Rate Concerns MT
SVB Securities Adjusts Amarin's Price Target to $2 From $3, Maintains Market Perform Rating MT

More recommendations

Press releases Amarin Corporation plc

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference GL
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference AQ
Amarin: Q1 Earnings Snapshot AQ
Amarin Reports First Quarter 2024 Business Update and Financial Results GL
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event GL

More press releases

News in other languages on Amarin Corporation plc

Amarin reçoit un remboursement pour VAZKEPA® en Suède
Amarin recibe reembolso por VAZKEPA® en Suecia
Amarin erhält Kostenerstattung für VAZKEPA® in Schweden
Une récente analyse démontre que VASCEPA® (icosapent éthyl) a considérablement réduit le risque d'événements cardiovasculaires potentiellement mortels chez des patients ayant déjà subi une intervention coronaire percutanée
Jüngste Analysen zeigen, dass VASCEPA® (Icosapent-Ethyl) das Risiko potenziell tödlicher kardiovaskulärer Ereignisse bei Patienten mit vorheriger perkutaner Koronarintervention signifikant gesenkt hat

More news

Quotes and Performance

1 day-4.65%
1 week+2.05%
Current month-5.53%
1 month-5.14%
3 months-28.10%
6 months+6.25%

More quotes

Highs and lows

1 week

0.86

Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (5)

0.96

1 month

0.81

Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (6)

1.03

Current year

0.80

Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (7)

1.37

1 year

0.65

Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (8)

1.49

3 years

0.65

Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (9)

5.97

5 years

0.65

Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (10)

26.12

10 years

0.65

Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (11)

26.12

More quotes

Managers and Directors - Amarin Corporation plc

Managers TitleAgeSince

Patrick Holt CEO

Chief Executive Officer 52 23-07-17

Thomas Reilly DFI

Director of Finance/CFO 52 22-06-19

Jonathan Provoost CMP

Compliance Officer 55 Nov. 14
Members of the board TitleAgeSince

Louis Sterling BRD

Director/Board Member 45 23-02-27

Odysseas Kostas CHM

Chairman 49 23-02-27

Keith Horn BRD

Director/Board Member 66 23-02-27

More insiders

Quotes

Date Price Change Volume
24-05-17 0.87 -4.65% 980,207
24-05-16 0.9124 -2.51% 586,557
24-05-15 0.9359 +2.87% 559,139
24-05-14 0.9098 -1.11% 595,912
24-05-13 0.92 +7.92% 1,035,567

Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT

More quotes

Company Profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Sector

Calendar

2024-05-20 - H.C. Wainwright BioConnect Investor Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Amarin Corporation plc

Trading Rating

Investor Rating

ESG Refinitiv

C

More Ratings

Analysts' Consensus

Sell

Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (12)

Buy

Mean consensus

HOLD

Number of Analysts

3

Last Close Price

0.87USD

Average target price

1USD

Spread / Average Target

+14.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.

AMARIN CORPORATION PLC

0.00% 357M

VERTEX PHARMACEUTICALS INCORPORATED

+9.42% 115B

REGENERON PHARMACEUTICALS, INC.

+11.84% 106B

ARGENX SE

-1.05% 21.96B

BIONTECH SE

-14.15% 21.84B

GENMAB A/S

-5.29% 19.21B

BEIGENE, LTD.

-4.16% 18.08B

WUXI APPTEC CO., LTD.

-38.29% 17.71B

NEUROCRINE BIOSCIENCES, INC.

+7.99% 14.32B

SAREPTA THERAPEUTICS, INC.

+36.24% 12.42B

Bio Therapeutic Drugs

  1. Stock Market
  2. Equities
  3. AMRN Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities. BENEFIT NOW
"); InvestingChannelQueue.push(function() { aICTags["oop"] = ic_page.defineOutOfPageTag("4Traders/quotepages","zppOOP"); aICTags["oop"].setKval({"adslot":"d_OOP_1"}); aICTags["oop"].render(); }); while (aAdsQueue.length) { (aAdsQueue.shift())(); } InvestingChannelQueue.push(function() { displayViewableAds('InvestingChannel'); $( window ).scroll(function() { displayViewableAds('InvestingChannel'); }); }); }gaEvent('adspv', 'InvestingChannel', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '1658813');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });
Amarin Corporation plc Stock (AMRN) - Quote Nasdaq- MarketScreener (2025)
Top Articles
Latest Posts
Recommended Articles
Article information

Author: Kieth Sipes

Last Updated:

Views: 6669

Rating: 4.7 / 5 (47 voted)

Reviews: 94% of readers found this page helpful

Author information

Name: Kieth Sipes

Birthday: 2001-04-14

Address: Suite 492 62479 Champlin Loop, South Catrice, MS 57271

Phone: +9663362133320

Job: District Sales Analyst

Hobby: Digital arts, Dance, Ghost hunting, Worldbuilding, Kayaking, Table tennis, 3D printing

Introduction: My name is Kieth Sipes, I am a zany, rich, courageous, powerful, faithful, jolly, excited person who loves writing and wants to share my knowledge and understanding with you.